Compare Amphastar Pharmaceuticals Inc (AMPH) vs Boeing Co (BA) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Boeing (BA) trades at $222.28, down 0.37% on the day, with a bullish technical signal and strong analyst support. The stock shows improving fundamentals with 2025 revenue of $89.46B and net income of $2.24B, reversing previous losses. Recent news includes both positive developments like new aircraft orders and regulatory milestones, alongside ongoing safety concerns highlighted by recent incidents.

The outlook is cautiously optimistic with a $268.33 consensus price target representing 21% upside. Key opportunities include production expansion and defense contracts, while risks center on operational execution, debt burden, and persistent safety-related headline volatility that could impact investor confidence and regulatory timelines.